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Introduction: Clinical Translational Research and Rare Disease
There are more than 6,000 unique and identifiable rare diseases that together affect
millions of individuals. Underlying genetic etiology, information on surveillance, prognosis and
tailored medical treatments are crucial for optimal survival and quality of life for these patients.
Particularly when the genetic etiology of a disease is delineated, molecular pathways can be
defined and this unlocks potential discovery for additional conditions and mechanisms. Though
tremendous progress has been made, we only have specific treatments for approximately 200
rare disorders – and only a handful that could be considered an essential cure.
While having a molecular diagnosis for a patient’s rare disease can mean everything to
that family, it also holds high value to us in the scientific and medical communities.
Understanding multi-faceted biochemical pathways is usually spearheaded by investigating a
deficiency or an issue that causes a rare disease. However, all patients, even with the same rare
disease, are quite different. They have their own genetic milieu as well as environmental factors
that make their clinical story unique.
The work of defining these rare diseases that are being discovered on a regular basis is
imperative to support all, but especially levels T1, T2, and T3, of clinical translational research.
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Without a solid understanding of what the molecular diagnosis is capable of, we cannot address
the medical issues associated.
The work included in this dissertation is limited to my three most important first author
published manuscripts since starting the Clinical Translational Research (CTR) Mentored
Scholar’s Program through the University of Nebraska Medical Center. All are patient-inspired.
During these past five years, I have also been involved with 16 additional manuscripts
delineating the phenotype and care of rare disease. Two in this dissertation are devoted to
Myhre syndrome. I was first introduced to Patient M while a fellow in medical genetics. Now, 8
years later, I am on the Myhre Professional Advisory Board and receive routine requests to
provide medical opinions on this progressive condition. The first article outlines 5 new patients
with Myhre and was the first article defining the devastating cardiopulmonary issues that they
can have. It was recognized that this article could have such medical impact upon submission
that the editors recommended publishing it urgently as a rapid communication and it was
included in the AJMG Sequence publication as an article of high medical care impact. The
second article is the GeneReview for Myhre syndrome. In rare disease it is well-known in the
medical community that the go-to review for genetic diseases is the GeneReview. It is an invited
article and there is a rigorous editing process. This article is by far the most impactful published
work I have contributed to in my career. The third manuscript, PIGQ
Glycosylphosphatidylinositol-Anchored Protein (GPI-AP) Deficiency: Characterizing the
Phenotype, was published as a new syndrome article in the American Journal of Medical
Genetics. This is the first article describing this condition. The editor, Dr. Max Muenke, included
this article in his opening editorial of The Journal when referring to advances in identifying new
genetic disorders.

8

Chapter One:
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ABSTRACT

Myhre syndrome, a connective tissue disorder characterized by deafness, restricted
joint movement, compact body habitus, and distinctive craniofacial and skeletal
features, is caused by heterozygous mutations in SMAD4. Cardiac manifestations
reported to date have included patent ductus arteriosus, septal defects, aortic
coarctation and pericarditis. We present five previously unreported patients with
Myhre syndrome. Despite varied clinical phenotypes all had significant cardiac and/or
pulmonary pathology and abnormal wound healing. Included herein is the first report
of cardiac transplantation in patients with Myhre syndrome. A progressive and
markedly abnormal fibroproliferative response to surgical intervention is a newly
delineated complication that occurred in all patients and contributes to our
understanding of the natural history of this disorder. We recommend routine
cardiopulmonary surveillance for patients with Myhre syndrome. Surgical intervention
should be approached with extreme caution and with as little invasion as possible as the
propensity to develop fibrosis/scar tissue is dramatic and can cause significant morbidity
and mortality.

Key Words: Myhre syndrome; SMAD4; connective tissue disorder; restrictive
cardiomyopathy; TGFβ
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INTRODUCTION
Over 30 years ago Myhre and colleagues described a syndrome characterized by
deafness, dysmorphic facial features, thick or stiff skin, restrictive joint movement,
skeletal anomalies, and short stature with muscular/thick-appearing or “compact” body
habitus [Myhre et al., 1981]. Subsequent to the original publication, others have further
defined the facial, skeletal, respiratory and upper airway features of the syndrome and
have expanded the clinical phenotype to include variable neurodevelopmental features
[Rulli et al., 2004; Lopez-Cardona et al., 2004; Titomanlio et al., 2001; Burglen et al.,
2003; Bachmann-Gagescu et al., 2011, McGowen et al., 2011]. In 2011, the genetic
basis for Myhre syndrome was identified with documentation of mutations within a very
restricted range of SMAD4 [Caputo et al., 2012; Le Goff et al., 2012]. To date, SMAD4
mutations have been reported in 46 patients with Myhre syndrome (OMIM #139210)
[Le Goff et al., 2012; Caputo et al., 2012; Lindor et al., 2012; Al Ageeli et al., 2012;
Asakura et al., 2012; Picco et al., 2012; Ishibashi et al., 2014; Kenis et al., 2014; Michot
et al., 2014; Hawkes et al., 2015; Oldenburg, et al., 2015] with no report of a familial
case. While the clinical picture of Myhre syndrome has been further clarified with new
reports of molecularly proven cases, there remains a paucity of data on the
cardiopulmonary aspects of the disorder, which may be progressive and fatal. We
report five new Myhre syndrome patients with SMAD4 mutations, three of whom died
of severe cardiac disease, and provide delineation of the associated fibrotic
complications.
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CLINICAL REPORTS
Patient 1
The patient was born small for gestational age (SGA) at term to healthy,
nonconsanguineous 29 year old parents. When seen for initial genetic evaluation as a
toddler she was noted to have progressive conductive hearing loss, mild developmental
delay, dysmorphic craniofacial features, recurrent choanal stenosis, short stature,
hyperopia, advanced bone age, 11 rib pairs, dermal thickening and compact build
(Figure 1). Echocardiogram at that time demonstrated a moderate-sized secundum
atrial septal defect (ASD) but no valvar abnormalities. Genetic studies at this time
included a normal 46,XX karyotype, normal 180K microarray (hg 18), and normal
CREBBP sequencing. On routine cardiac followup at one year of age the patient was
noted to have a small ASD and no other cardiac defects. At seven years of age the
patient was evaluated for a new murmur with symptoms of heart failure.
Echocardiography at that time demonstrated polyvalvar thickening with moderate
mitral valvar stenosis and normal subvalvar apparatus, mild mitral regurgitation, a
trileaflet aortic valve with moderate aortic stenosis, mild aortic regurgitation, concentric
left ventricular hypertrophy (LVH), mild tricuspid insufficiency and a diffusely small
aortic arch without focal narrowing. Further genetic studies included normal
sequencing of ADAMTSL2 and FBN1 as well as deletion/duplication analysis. Targeted
sequencing of SMAD4 then revealed a c.1499T>C (p.Ile500Thr) mutation.
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The patient developed rapid progression of her aortic stenosis and four months
later underwent cardiac catheterization. At catheterization, the valve appeared rubbery
and dysplastic with easy resolution of narrowing on balloon inflation. However, due to
the rubbery nature of the valve, no reduction in gradient could be achieved with a
standard-sized balloon. A result was achieved after a second valvuloplasty with a larger
balloon with a fall in the peak to peak gradient from 50 to 20 mmHg. The improvement,
however, was quite transient. Both right and left ventricular end-diastolic pressures
were elevated at 15mmHg, consistent with mild to moderate restrictive physiology.
One month following the procedure the patient was again documented to have
progressive aortic valvar stenosis as well as mitral stenosis. Eight months following
aortic valvuloplasty the patient underwent surgical aortic valve repair, tricuspid
valvuloplasty, ASD closure and mitral valve replacement following a failed attempt at
mitral valve repair. The mitral valve was characterized by severe fibrosis and dystrophic
calcification of the leaflets and subvalvar apparatus. Aortic valvar, subvalvar and
supravalvar fibrosis and calcification were also noted with fibrotic tissue partially
covering the right coronary ostia. The tricuspid valve was not fibrotic but had a
dysplastic cleft in the anterior leaflet. Surgery was complicated by complete heart block
requiring pacemaker placement on postoperative day 10. At the time of pacemaker
placement the midline fascia below the sternotomy was noted to be abnormally
thickened. In addition, the epicardial surface of the heart was noted to be unusually
rubbery and fibrotic. Over the next two months the patient developed progressive
heart failure secondary to a restrictive cardiomyopathy culminating in sudden cardiac
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arrest and placement on extracorporeal membrane oxygenator (ECMO). Left atrial
pressure was markedly elevated at 35mmHg despite a functioning, appropriately-sized
mechanical mitral valve. Cardiac catheterization was performed for the purposes of
creating an ASD for left heart decompression. Left ventricular function remained
severely impaired and the patient underwent cardiac transplantation. Cardiac
transplantation was complicated by inability to oxygenate requiring ECMO support for
one week, inability to obtain chest closure despite an appropriately-sized donor heart,
progressive SVC anastomotic narrowing requiring stenting, respiratory failure with
inability to wean from the ventilator, and progressive low cardiac output without
evidence of rejection requiring repeat ECMO support two months post transplantation.
The patient suffered an intracerebral bleed while on ECMO support and care was
withdrawn. She was eight years old.
Patient 2:
The patient was the second child of healthy, nonconsanguineous parents
(maternal age 29 years; paternal age 37 years). She was born SGA at term. The
pregnancy was complicated by polyhydramnios and prenatally diagnosed duodenal
atresia. The intestinal defect was repaired on the first day of life. Routine
echocardiogram demonstrated mild coarctation of the aorta. The subsequent clinical
course was characterized by dysmorphic craniofacial features (Figure 2), persistent short
stature, velopharyngeal insufficiency requiring a palatal lengthening procedure,
recurrent ear infections requiring placement of multiple sets of bilateral myringotomy
tubes, and superimposed bilateral sensorineural hearing loss resulting in severe speech
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delay. Overall development was mildly delayed. Skeletal survey showed a narrow
sciatic notch, short metacarpals and 11 rib pairs. At seven years of age the aortic
coarctation was refractory to balloon angioplasty, for which she underwent stent
placement. Despite adequate relief of aortic arch obstruction, the patient developed
elevation in pulmonary vascular resistance and was subsequently diagnosed with
restrictive cardiomyopathy, interstitial lung disease, and pulmonary hypertension.
Pulmonary function testing revealed a severely reduced FEV1 with no response to
bronchodilator therapy. Open lung biopsy was performed at 10 years of age which
demonstrated diffuse interstitial fibrosis, medial thickening of arteries, arterioles and
veins and smooth muscle hyperplasia of the airways with a large amount of collagen
present. She had progression of her restrictive cardiomyopathy over a period of three
years and underwent bilateral heart and lung transplantation. Transplantation was
complicated by diffuse mediastinal fibrosis (pericardium was noted to be normal) and
adhesions requiring extensive care in removing. Post-transplant her chest was able to
be closed, however, she suffered persistent respiratory failure and blood pressure
lability. She suffered an ECMO-related stroke and died 6 days postoperatively at 12
years of age.
The explanted heart demonstrated no abnormality of the pericardium but
diffuse fibrosis of the endocardium and subendocardium. Explanted lungs
demonstrated diffuse interstitial fibrosis with septal widening and pneumocyte
hyperplasia. SMAD4 sequencing performed post-mortem from previously extracted
DNA for other genetic studies (46,XX karyotype, 22q11.2 FISH, chromosome breakage
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studies, Feingold studies [MYCN sequencing and deletion/duplication analysis]),
confirmed a c.1499T>C (p.Ile500Thr) mutation consistent with the diagnosis of Myhre
syndrome.
Patient 3:
The patient was born SGA to nonconsanguineous parents at term (maternal age
28 years; paternal age 30 years). The clinical course was marked by dysmorphic
craniofacial features (Figure 3) significant feeding and swallowing difficulties as an
infant. At 24 months she charted at below the 5th centile for stature; approximately the
50th centile for a 10 month old. Her upper airway was thoroughly evaluated and no
obstruction was found, although absent nasal cilia were noted. Over time she had
persistence of short stature, progressive conductive hearing loss, progressive skin
changes marked by dermal thickening, menorrhagia refractory to medical therapy, and
at age 17 presented with unilateral vision loss due to biopsy-confirmed right optic nerve
sheath meningioma. The patient had normal intelligence, but required medical
treatment of obsessive-compulsive and anxiety disorders. Her initial cardiac evaluation
was performed at age two years at which time she was diagnosed with an innocent
murmur with normal echocardiogram. A repeat echocardiogram at age four years
documented normal cardiac anatomy. At age 16 she was again evaluated by cardiology
for dyspnea and hypertension. Spirometry revealed moderate to severe restrictive lung
disease which was felt to be secondary to musculoskeletal deformity due to her
dwarfism. Echocardiogram documented mild aortic stenosis and normal ventricular
function. Hypertension was well controlled on two medical agents.
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Over a period of eight years her aortic valve stenosis became progressively more
severe with a peak to peak gradient of 80 mmHg. Aortic balloon valvuloplasty was
performed. This also required upsizing of the balloon, with the valve appearing
dysplastic. A reduction in gradient from 80 to 35 mmHg was achieved. The patient had
persistent elevation of both right- and left-sided filling pressures consistent with
restrictive physiology. Myhre syndrome was diagnosed at this time with confirmation of
a c.1498A>G (p.Ile500Val) mutation in SMAD4. Over the ensuing two years the patient
developed progressive shortness of breath with LVH and progressive aortic stenosis
requiring repeat valvuloplasty attempt at age 26 years. Just prior to her catheterization
she was unable to walk across the room or eat a meal without distress. At
catheterization, the anesthesia team found her respiratory mechanics to be significantly
compromised and counselled the family that she may not tolerate extubation. The
catheterization documented progressive aortic stenosis (gradient of 78mmHg), and
marked elevation in diastolic pressures in both ventricles. The intervention produced
minimal improvement in the aortic valve (reduction to 55mmHg), despite two larger
balloon attempts. No aortic insufficiency was created. She was transferred to the ICU,
but was unable to wean from mechanical ventilation. After discussion with her family
regarding her severely compromised cardiac and lung function, her family elected not to
proceed with resuscitation; when she received an optimized trial of extubation, she was
unable to maintain adequate ventilation and died.
Patient 4:
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The patient was born SGA 3 days prior to due date to 26 year old
nonconsanguineous parents. He had poor feeding, gastroesophageal reflux, and
subglottic stenosis. His motor development was mildly delayed and at two years of age
bilateral hearing loss was found on evaluation for delayed speech. He was found to be
growth hormone deficient and placed on growth hormone at age eight. Since starting
growth hormone he has progressed from the 5th centile to the 30th centile for height (at
13 years of age). He had seen genetics at seven years of age for evaluation of
dysmorphic craniofacial features (Figure 4a-c), hypotonia, hearing loss, restricted finger
joint movement (Figure 4d), and short stature which resulted in a normal microarray
and Noonan syndrome testing. At nine years of age he underwent choanal stenosis
repair. Spirometry demonstrated persistent restrictive lung disease without response to
albuterol. He had a diagnostic right deltoid muscle biopsy which showed small striated
muscle fibers of minimal size variation. Histologic analysis showed esterase-positive
cellularity within the epimysial connective tissue. The biopsy site required several
weeks to heal and resulted in a large fibrotic scar (Figure 4e). He had normal
echocardiograms at 6 and 11 years of age. On follow up with genetics, at 11 years of
age he was recognized to have findings of Myhre syndrome; SMAD4 targeted testing
confirmed a c.1498A>G (p.Ile500Val) mutation. By 13 years of age he had a total of nine
sets of myringotomy tubes and continues to have restrictive pulmonary disease but
otherwise well, and is attending school full time.

Patient 5:
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The fifth patient was born SGA at 37 weeks gestation to healthy
nonconsanguineous parents (maternal age 25 years; paternal age 28 years) with a
noncontributory family history. On clinical genetics evaluation at four years of age she
was noted to have dysmorphic craniofacial features (Figure 5a-c), bilateral hearing loss
(right ear primarily conductive; left ear mixed), strabismus, velopharyngeal insufficiency,
asthma, gastroesophageal reflux, prior gastric fundoplication, mild periventricular
leukomalacia, limited joint extensibility, and speech and gross motor delays. She had
normal social development and intelligence. At that time height was 94 cm, (3rd
centile), weight was 14.2 kg (10th centile) and head circumference was 50.1 cm (45th
centile). She had a flat nasal bridge, a systolic murmur, and limited movement of the
joints. Subsequent clinical course was significant for tonsillectomy and adenoidectomy
at age seven years. At age eight years she underwent a superiorly based pharyngeal
flap and was noted to have vocal cord paresis and subglottic stenosis with scarring of
the vocal cords. She was found to have fusion of the C6 and C7 vertebral bodies with
widening of the C5-C6 disc space (Figure 5d). She was diagnosed with systemic
hypertension and suffered multiple episodes of otitis media and pneumonias with
pleural effusion. She had hypogammaglobulinemia with recurrent variable infections
which has responded to IVIG treatment.
At 12 years of age she presented with cough and positional dyspnea.
Echocardiogram demonstrated a very large pericardial effusion and severe reduction in
left ventricular systolic function with shortening fraction of 10%. Ventricular chambers
were normal in size but both atria were dilated. Following drainage of her pericardial
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effusion her ventricular function remained poor with evidence of abnormal diastolic
function with an E/A ratio > 3:1. During this evaluation intubation required multiple
attempts and special measures. She was transferred to a tertiary care center for
consideration of advanced heart failure therapies. She was diuresed and started on
inotropic support with recovery of ventricular function within 24 hours. One year later
the patient developed diffuse edema and dyspnea. Evaluation at that time
demonstrated normal sized ventricles with preserved systolic function, dilated atria,
abnormal mitral inflow as noted previously, a small pericardial effusion, and elevated
BNP consistent with constrictive or restrictive physiology. As part of her vascular
workup for chronic hypertension, she was noted to have a diffusely small descending
aorta and focal stenosis of the celiac artery. At 13 years of age, the patient developed
progressive sublaryngeal stenosis and a tracheostomy was performed. At followup she
was noted to have a shelf of scar tissue with complete soft tissue stenosis of the airway.
Both her fundoplication (Figure 5e) and tracheostomy incisions resulted in a
hypertrophic scar.
Normal genetic studies throughout her course included an amniocentesis 46,XX
karyotype, 22q11.2 FISH, subtelomere FISH, and microarray analysis (2013). At 14 years
of age SMAD4 sequencing showed a c.1499T>C (p.Ile500Thr) mutation.
At 15 years of age the patient continues to have significant issues with severe
subglottic stenosis that had progressed to grade IV, resulting in inability to vocalize;
evaluation for laryngotracheal reconstruction was in process.
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DISCUSSION
Myhre syndrome is caused by apparent gain-of-function mutation in SMAD4
which, to date, appear to be restricted to heterozygous missense changes in Ile500
within the conserved MAD homology 2 domain of exon 11 [Caputo et al., 2012; LeGoff
et al., 2012; LeGoff, et al., 2014] in all but three reported patients. In these three
patients with a clinical phenotype of Myhre syndrome, an Arg496 change [Caputo et al.,
2014; Michot et al., 2014] was instead documented. These patients were of normal
stature and did not have cardiac anomalies. While the Arg496 residue is involved in the
transcriptional activation of SMAD4 it only results in dysregulation via altered
expression of matrix metalloproteinases (MMPs) which act as a major contributor to
extracellular matrix (ECM) stability [Caputo et al., 2014; Piccolo et al., 2014]. In contrast,
the more typical Ile500 aberrations affect the MMPs as well as their related inhibitors
[Piccolo et al., 2014].
In Myhre syndrome, because of decreased mono-ubiquitination, stability is
inferred upon the SMAD4 protein which disrupts TGFβ signaling, resulting in abnormal
development of axial and appendicular skeletal structures, skeletal and cardiac muscular
development as well as the central nervous system [Caputo, 2012; Le Goff, 2014]. The
role of the SMADs has been well established in a spectrum of acquired cardiac diseases,
including cardiac fibrosis and hypertrophy, aortopathies, atherogenesis and pulmonary
artery hypertension. SMAD4, a central cytoplasmic mediator of the TGF-β and BMP
signaling pathways, has been shown to have increased expression in patients with
cardiac atrial fibrosis [Gramley et al., 2010].
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Although there has not been a Myhre syndrome-specific mouse model, there
have been other mouse models looking at the role of SMAD4 as it relates to cardiac
form and function. A mouse model with cardiac myocyte-specific disrupted SMAD4
developed heart failure secondary to significant cardiomyocyte hypertrophy and cardiac
fibrosis [Wang et al., 2005]. Cardiac tissue fibrosis has also been induced in cardiac
fibroblasts from a mouse model directly targeting SMAD4, increasing the profibrogenic
TGF- β1 activity [Huang et al., 2014]. A keratinocyte-specific SMAD4 knockout mouse
has been shown to have a significantly accelerated rate of keratinocyte proliferation and
wound contraction [Yang et al., 2012].
We present five previously unpublished patients with Myhre syndrome with
documented SMAD4 missense mutations in the isoleucine residue at position 500 (Table
I). While all share cardinal features of progressive hearing loss, restricted joint
movement, thick skin, and compact habitus, they also demonstrate impressive
variability in clinical expression. We are not aware of any prior reports of need for
cardiac transplantation in this patient population. While minor cardiac involvement has
been reported in many patients with Myhre syndrome the need for and outcome of
surgical intervention, has not been thoroughly described. Constrictive pericarditis has
been reported in LAPS (Laryngotracheal stenosis, Arthropathy, Prognathism, and Short
stature) syndrome, a condition determined to be a phenotypic variant of Myhre
syndrome by Lindor et al. in 2012 [Picco et al., 2013; Michot et al., 2014]. In Lindor’s
series, one patient who underwent pericardectomy for presumed constrictive
pericarditis, had persistent restrictive indices on echocardiography suggesting that
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restrictive cardiomyopathy may have been the underlying disease process as it was in
the four patients we describe with cardiomyopathy.
Specifically, Myhre syndrome patients undergoing transplantation have not been
previously reported and we present two patients who were unable to survive posttransplantation complications. These patients had significant fibrotic scarring of the
heart itself and surrounding mediastinal structures from presumed previous tissue
damage or instrumentation. Of note, the pericardium itself was noted to be normal in
these three patients where the pericardium was inspected intraoperatively or on
autopsy. This article highlights a potential deleterious effect of surgery in these patients
with abnormal tissue response resulting in impaired wound healing, anastamotic
strictures, and adverse myocardial remodeling. Prior concern about wound healing in
Myhre syndrome was raised by Lindor et al, noting life-threatening adhesions following
hysterectomy in a patient who also had chronic restrictive cardiomyopathy which
persisted after pericardectomy [Lindor et al., 2012].
In addition, Myhre syndrome patients are prone to complicated airway
management. Post-intubation/tracheal-trauma fibrotic scarring resulting in grade IV
stenosis is presumed in Patient 5 and has also been reported in multiple other patients
with Myhre syndrome [Oldenburg et al., 2015] and we recommend extraordinary
caution with intubation.
The decision to take a patient with Myhre syndrome to surgery of any kind
should include a discussion of an apparently abnormal wound healing process, abnormal
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adhesions and fibrosis that could impact overall success and both short- and long-term
morbidity and mortality. The potential for current and future difficult airway
management should also be reviewed. For all Myhre syndrome patients, serial
echocardiograms should be performed to detect progressive valvar and myocardial
disease. We recommend an echocardiogram at the time of diagnosis of Myhre
syndrome and at a minimum of every two years thereafter or if symptoms arise. In
addition, prompt referral for pulmonary evaluation with functional testing should be
performed if symptoms suggest compromise, due to the increased risk for restrictive
pulmonary insufficiency. Patients with Myhre syndrome should be closely monitored
post-operatively for abnormal fibrotic wound healing and elective surgical procedures
should be avoided if at all possible given the attendant risks.
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TABLE I. Clinical details and newly reported features of the patients reported in this
manuscript.

*hearing loss, typical facial features, compact build, restricted joint movement, thick
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FIGURES and LEGENDS

FIG 1. Patient one at seven years of age. Note midfacial retrusion, relative prognathism,
flat nasal bridge, downward pointing nasal tip, microstomia, wide-spaced teeth, thin
upper lip, broad ears with a squared shape, limited facial creasing, broad and short neck
with an overall compact body habitus. She has brachydactyly and fingers are not
CApable of full extension.
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FIG 2. Photos of the patient 2 at 1, 2, 3, 5, 10 (standing) and 12 years of age. Note
progression of features with midfacial retrusion, prognathism, flat nasal bridge,
downward pointing nasal tip, microstomia, thin upper lip, broad ears with a squared

27

shape, limited facial creasing, broad and short neck with compact body habitus.

FIG 3. Photos of patient 3 at 23 years of age. Note midfacial retrusion, flat nasal bridge,
downward pointing nasal tip, microstomia, thin upper lip, prognathism, broad ears with
a squared shape, limited facial creasing, broad neck and low posterior hairline.
Brachydactyly with limited extension and lordosis is also present.
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FIG 4a-d. Photos of patient 4 at 7 (a) and 11 (b,c) years of age. Note the mild features
of this patient. Broad and flat nasal bridge, mild midfacial retrusion with relative
prognathism. Mild brachydactyly is present with limited small and large joint extension
(d).
FIG 4e. Hypertrophic scar subsequent to uncomplicated muscle biopsy.
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FIG 5a-c. Photos of patient 5 at 3 and 15 years of age. Note progression of midfacial
retrusion and prognathism. This patient has a lateral ptosis, low hanging columella,
square and broad ears and minimal facial creasing.
FIG 5d. Radiograph of cervical vertebrae at 11 years of age show an anterior bar fusing
C2 to C3 and fusion of the C6 and C7 vertebral bodies with widening of the C5-C6 disc
space.
FIG 5e. Hypertrophic scars at fundoplication incision site.
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Summary
Clinical characteristics.
Myhre syndrome is a connective tissue disorder with multisystem involvement, progressive and
proliferative fibrosis that may occur spontaneously or following trauma or surgery, mild-tomoderate intellectual disability, and in some instances, autistic-like behaviors. Organ systems
primarily involved include: cardiovascular (congenital heart defects, long- and short-segment
stenosis of the aorta and peripheral arteries, pericardial effusion, constrictive pericarditis,
restrictive cardiomyopathy, and hypertension); respiratory (choanal stenosis, laryngotracheal
narrowing, obstructive airway disease, or restrictive pulmonary disease), gastrointestinal
(pyloric stenosis, duodenal strictures, severe constipation); and skin (thickened particularly on
the hands and extensor surfaces). Additional findings include distinctive craniofacial features
and skeletal involvement (intrauterine growth restriction, short stature, limited joint range of
motion). To date, 55 individuals with molecularly confirmed Myhre syndrome have been
reported.
Diagnosis/testing.
The diagnosis of Myhre syndrome is established by detecting a de novo SMAD4 heterozygous
pathogenic variant in a proband with characteristic clinical findings.
Management.
Treatment of manifestations: Symptomatic treatment (with attention to limiting tissue trauma
by minimizing instrumentation during diagnosis and management) by specialty experts of the
following involvement: cardiovascular, respiratory (including tracheostomy when tracheal
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stenosis is recurrent or complete), and GI; routine management of speech and language delay,
intellectual disability, behavioral problems.
Prevention of secondary complications: Limiting of tissue trauma given the apparent increased
risk for proliferative fibrosis following otherwise uncomplicated endotracheal intubation and
surgical procedures. When possible, alternative noninvasive approaches should be pursued
during diagnosis and management
Surveillance: Cardiovascular: echocardiogram every one to three years in asymptomatic
individuals with a normal echocardiogram at the time of initial diagnosis; in individuals with
abnormal cardiac findings at the time of diagnosis, more extensive imaging (including possible
cardiac MRI) may be considered. Respiratory: oxygen saturation in children with monitoring as
needed for symptoms suggestive of restrictive/obstructive pulmonary disease; annual
pulmonary function studies in children oldert than age six years if able to cooperate; evaluation
of laryngotracheal stenosis based on symptoms. Annual ophthalmology and audiology
evaluations.
Agents/circumstances to avoid: Smoking; tissue trauma.
Genetic counseling.
Myhre syndrome is inherited in an autosomal dominant manner. All probands with Myhre
syndrome reported to date have the disorder as a result of a de novo SMAD4 pathogenic
variant. If the SMAD4 pathogenic variant found in the proband cannot be detected in the
leukocyte DNA of either parent, the risk to sibs is presumed to be slightly greater than that of
the general population (though still <1%) because of the theoretic possibility of parental
germline mosaicism. To date, individuals with Myhre syndrome are not known to reproduce and
fertility has not been assessed. Once the SMAD4 pathogenic variant has been identified in an
affected family member, prenatal testing for a pregnancy at theoretic increased risk for Myhre
syndrome and preimplantation genetic diagnosis are possible.
Diagnosis
Formal diagnostic criteria have not been published for Myhre syndrome.
Suggestive Findings
Myhre syndrome should be suspected in individuals with the following clinical and radiographic
findings.
Clinical
Cardiovascular
Arterial obstruction: juxtaductal coarctation of the aorta, long- and short-segment descending
thoracic and abdominal aortic obstruction, and peripheral arteries in various locations;
infrequently, branch pulmonary artery stenosis
Congenital heart defects:
Atrial and ventricular septal defects, patent ductus arteriosus
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Valvular stenosis: aortic and mitral valves; infrequently, tricuspid and pulmonic valves
Pericardial involvement: ranges from effusion to constrictive pericarditis; often chronic and
severe
Restrictive cardiomyopathy (can be rapidly progressive)
Hypertension: systemic and pulmonary
Respiratory (congenital or acquired)
Laryngotracheal narrowing (including subglottic stenosis)
Choanal stenosis
Obstructive airway disease
Restrictive pulmonary disease (which appears to increase with age)
Gastrointestinal
Congenital or acquired pyloric stenosis
Later onset:
Duodenal strictures
Severe constipation
Skin
Stiff and thickened overall, but particularly on the hands and extensor surfaces
Facial creases fewer than expected for age
Proliferative fibrosis/scarring
May occur spontaneously or following trauma or surgery
May involve the serosal surfaces of the heart, airway and lungs, and gastrointestinal tract as well
as the skin
Neuropsychiatric
Mild-to-moderate intellectual disability
Autistic-like behaviors in some
Craniofacial
Characteristic facial features including short palpebral fissures, deeply set eyes, maxillary
underdevelopment, short philtrum, narrow mouth, thin vermilion of the upper lip, and
prognathism (Figure 1, Figure 2, Figure 3, Figure 4, Figure 5). Facial characteristics can progress
over time; although classic coarsening of features is not present, mandibular elongation is
notable. Note: Craniofacial features can vary considerably.
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Cleft lip and/or palate and velopharyngeal insufficiency reported in 13% [Lin et al 2016]

Figure 1.
Female with Myhre syndrome at ages seven months, four years, and 16 years. Note the short
palpebral fissures, thin upper vermilion border and maxillary underdevelopment. She required
tracheostomy subsequent to traumatic intubations that resulted in complete tracheal stenosis

Figure 2.
Female with Myhre syndrome at ages newborn, 12 months, 3.5 years, and seven years. Note the
short palpebral fissures, thin upper vermilion border, and progression of mild prognathism.
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Figure 3. . Female with Myhre syndrome at ages three years, ten years (standing), and 21 years
(face, posterior hairline, and hands).
Female with Myhre syndrome at ages three years, ten years (standing), and 21 years (face,
posterior hairline, and hands). Note the short palpebral fissures, broad mid-upper nasal bridge,
downward pointing nasal tip, thin upper vermilion border, broad and short neck, contracted
joints (elbows are fully extended in photos), brachydactyly, and compact habitus.

Figure 4.
Male with Myhre syndrome at age 12 years. Note the mild facial features (mild maxillary
underdevelopment and thin upper vermilion border) and finger contractures (hands are on a
flat surface).
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Figure 5. . Female with Myhre syndrome at age five years.
Female with Myhre syndrome at age five years. Note the short palpebral fissures, thin upper
and lower vermilion borders, left-sided facial palsy, and brachydactyly with otherwise mild
features. Facial palsy is observed in 4% of individuals with Myhre syndrome [Lin et al 2016].
Skeletal
Infants typically have intrauterine growth restriction (IUGR)
Short stature (height is significantly less than that predicted by parental heights) with compact
body habitus
Range of motion of the joints can be limited
Radiographic
Findings include the following:
Thickened calvarium
Shortened long bones
Brachydactyly
Broad ribs
Enlarged vertebrae with shortened pedicles; vertebral fusion
Hypoplastic iliac wings
See Figure 6.
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Figure 6.
Radiographs of a female age 14 years A. Thickened calvaria and anterior cervical vertebral fusion
(arrow) of C2 and C3
Establishing the Diagnosis
The diagnosis of Myhre syndrome is established in a proband with characteristic clinical findings
and a de novo heterozygous pathogenic variant in SMAD4 detected by molecular genetic testing
(see Table 1).
Molecular genetic testing approaches can include a combination of gene-targeted testing
(multigene panel or single-gene testing) and genomic testing (comprehensive genome
sequencing).
Gene-targeted testing requires the clinician to determine which gene(s) are likely involved,
whereas genomic testing may not. Persons with the distinctive findings described in Suggestive
Findings are likely to be diagnosed using gene-targeted testing (see Option 1), whereas those in
whom a specific diagnosis has been elusive are more likely to be diagnosed using genomic
testing (see Option 2).
Option 1
When the phenotypic and radiographic findings suggest the diagnosis of Myhre syndrome,
molecular genetic testing approaches can include single-gene testing or use of a multigene
panel:
Single-gene testing. Sequence analysis of SMAD4 is performed first. If no pathogenic variant is
found, gene-targeted deletion/duplication analysis may be considered; to date, however, no
exon or whole-gene deletions have been reported.
A multigene panel that includes SMAD4 and other genes of interest (see Differential Diagnosis)
may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity
of the testing used for each gene vary by laboratory and over time. (2) Some multigene panels
may include genes not associated with the condition discussed in this GeneReview; thus,
clinicians need to determine which multigene panel is most likely to identify the genetic cause of
the condition at the most reasonable cost while limiting identification of variants of uncertain
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significance and pathogenic variants in genes that do not explain the underlying phenotype. (3)
In some laboratories, panel options may include a custom laboratory-designed panel and/or
custom phenotype-focused exome analysis that includes genes specified by the clinician. (4)
Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or
other non-sequencing-based tests.
For an introduction to multigene panels click here. More detailed information for clinicians
ordering genetic tests can be found here.
Option 2
When the diagnosis of Myhre syndrome has not been considered, genomic testing
(comprehensive genome sequencing), when available, is likely to be the diagnostic modality
selected. Comprehensive genome sequencing includes exome sequencing and genome
sequencing.
For an introduction to comprehensive genomic testing click here. More detailed information for
clinicians ordering genomic testing can be found here.
Table 1.
Molecular Genetic Testing Used in Myhre Syndrome
Gene 1 Test Method
Sequence analysis 3
SMAD4

Proportion of Probands with a Pathogenic
Variant 2 Detectable by This Method
55/55 4

Gene-targeted deletion/duplication
Unknown 6
analysis 5

1. See Table A. Genes and Databases for chromosome locus and protein.
2. See Molecular Genetics for information on allelic variants detected in this gene.
3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic.
Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants;
typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence
analysis results, click here.
4. 54 patients summarized by Lin et al [2016] and one patient reported by Bassett et al [2016]
5. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include: quantitative
PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect
single-exon deletions or duplications.
6. No data on detection rate of gene-targeted deletion/duplication analysis are available.

Clinical Description
Myhre syndrome is a multisystem connective tissue disorder involving: the cardiovascular
system, respiratory system, gastrointestinal tract, and skin; progressive and proliferative fibrosis
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that may occur spontaneously or following trauma or surgery, often resulting in significant
complications; mild-to-moderate intellectual disability; and behavioral issues in some.
Additional findings include distinctive craniofacial features and skeletal involvement.
Myhre syndrome was first described by Myhre et al [1981] in two unrelated males. Since 2011,
when heterozygosity for a SMAD4 pathogenic variant was found to be causative, 55 affected
individuals with a molecularly confirmed diagnosis of Myhre syndrome have been reported. Lin
et al [2016] reported four affected individuals and summarized findings in 50 previously
reported individuals [Le Goff et al 2011, Al Ageeli et al 2012, Asakura et al 2012, Caputo et al
2012, Lindor et al 2012, Picco et al 2013, Ishibashi et al 2014, Kenis et al 2014, Michot et al 2014,
Hawkes & Kini 2015, Oldenburg et al 2015, Starr et al 2015]. Subsequently Bassett et al [2016]
reported one additional affected individual.
Note: Unless otherwise noted, the following findings are reported in Lin et al [2016].
Infancy and progression of findings. In infancy, characteristic facial features are usually present,
but more difficult to recognize than in an older child (see Suggestive Findings and Figure 1,
Figure 2, Figure 3, Figure 4, Figure 5). Short stature and hearing loss develop over time as well as
the highly distinctive (and often severe) findings of Myhre syndrome: joint stiffness, restrictive
lung and cardiovascular disease, progressive and proliferative fibrosis, and thickening of the
skin.
Cardiovascular. Of 54 individuals with a confirmed molecular diagnosis of Myhre syndrome, 70%
had a cardiovascular abnormality including structural heart defects (63%); pericardial disease
(17%), restrictive cardiomyopathy (9%), and systemic hypertension (15%).
Cardiovascular abnormalities include the following:
Atrial septal defect (4%) and ventricular septal defect (6%)
Patent ductus arteriosus (which can be large) (20%)
Obstructive defects of the left heart, such as juxtaductal aortic coarctation (15%), long-segment
aorta narrowing (6%), aortic valve stenosis (15%), and mitral valve stenosis (2%). These are more
common than obstructive defects of the right-side, such as valvar and branch pulmonary artery
stenosis [Michot et al 2014, Hawkes & Kini 2015, Starr et al 2015].
Peripheral vascular stenoses (in celiac and/or renal arteries) (7%)
Of note, complex congenital heart defects are not observed.
Pericardial disease (reported in 17%) can present as a short-term or recurrent effusion or as
chronic or progressive constrictive pericarditis that may require surgical intervention (see
Management).
Restrictive cardiomyopathy, a lethal condition, is the least common form of cardiomyopathy in
the general population and can be overlooked unless cardiac catheterization documents the
characteristic hemodynamics.
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While constrictive pericarditis and restrictive cardiomyopathy can present with similar
hemodynamics, they differ in pathogenesis and treatment (see Management).
Pulmonary hypertension has been infrequently reported; however, this may reflect limited
evaluation and/or bias toward ascertainment and/or reporting of younger patients (as
underlying causes of pulmonary hypertension resulting from involvement of the lungs and
cardiovascular circulation may evolve with age).
Progressive cardiovascular issues can appear at any age; those with onset in childhood may
worsen following instrumentation: two patients with restrictive cardiomyopathy who were
treated with heart and heart/lung transplantation did not survive postoperative complications
[Starr et al 2015].
Respiratory. Respiratory issues can be multifactorial. Airway stenosis, typically involving the
larynx and trachea, has included subglottic stenosis (17%) that can be recurrent and severe. Less
common is upper airway obstruction due to choanal stenosis (11%).
Restrictive and obstructive pulmonary disease are major causes of morbidity at all ages.
Interstitial lung disease has been described. Severe pulmonary fibrosis has been noted on
autopsy [Starr et al 2015].
Gastrointestinal involvement
Duodenal atresia 3/54 (6%)
Late-onset pyloric stenosis [L Starr, personal observation]
Protein-losing enteropathy (Patient 1 [Lin et al 2016])
Severe constipation [Michot et al 2014, Starr et al 2015]
Cutaneous. Generalized thickening/stiffness of the skin is seen in nearly all individuals with
Myhre syndrome. Various terms used to describe the skin include thick, stiff, firm, rough,
keratotic, and inelastic. Additional findings are minimal creasing of the facial skin and fibrous
and keloid-like scar formation.
Skin changes may not be apparent in infancy; they are often first noted on extensor surfaces,
palms, and soles. The changes progress with age.
Neuropsychiatric. Data are limited. Mild-to-moderate intellectual disability and global
developmental delay are common; however, cognition can be within the normal range. Of note,
acquired and unrecognized hearing loss may also contribute to speech delay and academic and
social challenges.
Findings of autism spectrum disorder have been noted in a minority of affected individuals
[Michot et al 2014].
Skeletal. The majority of affected infants have intrauterine growth restriction (41/49; 84%).
Short stature with compact body habitus (with normal head circumference) becomes more
apparent over time. Adult height is expected to be more than two standard deviations below
what is predicted by parental heights.
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Small hands and feet with brachydactyly is usually notable (see Figure 3, Figure 4, Figure 5).
Posture may be distinct with flexed elbows and bending forward at the hips (see Figure 3 and
Ishibashi et al [2014], Figure 1).
Reduced range of motion of large and small joints is characteristic and is exacerbated with age.
Walking on tiptoes is common.
Immune system. Recurrent infections (especially otitis media and pneumonia) have been
reported in 19 of 34 individuals. Increased susceptibility to infection has been associated with
immunoglobulin deficiency in three affected individuals; IVIG was utilized with reported benefit
in one affected individual [Starr et al 2015]. At this point, it is unknown if immune deficiency is
associated with Myhre syndrome or if it is an incidental finding [Michot et al 2014, Starr et al
2015].
Ophthalmologic. At least one abnormal eye finding was reported in 53% (26/49) of affected
individuals:
Strabismus 13/53 (24%)
Refractive errors in 17/53 (31%)
Other. Cataracts, astigmatism, and optic nerve sheath meningioma
Hearing loss is observed in most (83%) individuals with Myhre syndrome.
Hearing loss is predominantly conductive, but can be sensorineural and mixed. The underlying
etiology of the hearing loss is often unclear or unknown; most often patients have a history of
bilateral myringotomy tube placement.
Of note, most infants pass their newborn hearing screen. In the authors' experience hearing loss
usually becomes evident in early childhood and is typically present in adults.
Endocrine. Puberty has been reported to be normal, premature, or delayed. Secondary
amenorrhea has been reported.
Neoplasia
Endometrial carcinoma [Lindor et al 2012], optic nerve sheath meningioma [Starr et al 2015],
and mesencephalic glioma [Lin et al 2016] have each been reported once.
Telangiectasias and juvenile polyps, reported in heterozygotes for a SMAD4 loss-of-function
pathogenic variant, have not been reported in Myhre syndrome; however, information to date
is limited.
Genotype-Phenotype Correlations
The gain-of-function SMAD4 pathogenic variants that cause Myhre syndrome involve only two
protein residues (codons 496 and 500). To date, no clear genotype-phenotype correlations are
evident in affected individuals with either codon abnormality.
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Of note, although the three individuals reported with the p.Arg496C variant do not have
cardiovascular involvement and are taller in stature – two on the growth curve (2nd-25th
centile) and one <1st centile [Michot et al 2014, Caputo et al 2014] – the data are too limited to
draw any conclusions about genotype-phenotype correlations.
Penetrance
Penetrance appears to be complete; however, no familial cases of Myhre syndrome have been
reported.
Nomenclature
LAPS (laryngotracheal stenosis, arthropathy, prognathism, and short stature) syndrome was
determined to be a phenotypic variant of Myhre syndrome with pathogenic variants in the same
codons [Lindor et al 2012, Picco et al 2013, Michot et al 2014]; the term is no longer in use.
Prevalence
The prevalence is unknown.
Since 2011 when a heterozygous pathogenic variant in SMAD4 was discovered to be the cause
of Myhre syndrome, 55 affected individuals with a molecularly confirmed diagnosis have been
reported worldwide with no apparent ethnic or sex predilection (54 summarized in Lin et al
[2016] and one reported by Bassett et al [2016]).
Genetically Related (Allelic) Disorders
Other phenotypes known to be associated with germline pathogenic variants in SMAD4:
Juvenile polyposis syndrome (JPS)
Hereditary hemorrhagic telangiectasia (HHT)
Whereas Myhre syndrome is caused by heterozygous gain-of-function SMAD4 pathogenic
variants (see Molecular Genetics), JPS and HHT are caused by heterozygous loss-of-function
SMAD4 pathogenic variants.
Differential Diagnosis
The disorders that most closely resemble Myhre syndrome are the other acromelic dysplasias:
geleophysic dysplasia, acromicric dysplasia, and Weill-Marchesani syndrome, which share the
findings of thickened skin, short stature, short hands, and stiff joints. MULIBREY nanism should
also be considered.

Table 2.
Disorders to Consider in the Differential Diagnosis of Myhre Syndrome
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Clinical Features of the Disorder
Disorder

Gene(s)

Acromicric
dysplasia
FBN1
(OMIM 102370)

MOI

AD

ADAMTSL2 AR

Geleophysic
dysplasia 1

FBN1

FBN1



IUGR



Short stature



Brachydactyly



Joint stiffness



Thickened skin



IUGR



Short stature



Short hands and
feet



Progressive joint
limitation and
contractures

AD

ADAMTS10
AR
LTPBP2
WeillMarchesani
syndrome 2

Overlapping with Myhre
Syndrome

AD



Progressive
cardiac valvar
thickening



Thickened skin



IUGR



Short stature



Brachydactyly



Joint stiffness

Distinguishing from Myhre
Syndrome


Characteristic
external notch of
the fifth
metacarpal and
internal notch of
the femoral head



Absence of hearing
loss



Less frequent
cardiac anomalies



Absence of
calvarial thickening



Hepatomegaly



Characteristic
facies



Distinctive lens
abnormalities 2



Lack of hearing
loss
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Clinical Features of the Disorder
Disorder

Gene(s)

MULIBREY
nanism
TRIM37
(OMIM 253250)

MOI

Overlapping with Myhre
Syndrome


IUGR



Short stature



Relatively large
head



Constrictive
pericarditis



Restrictive
cardiomyopathy

AR

Distinguishing from Myhre
Syndrome



Shorter stature



Small tongue

MOI = mode of inheritance
AD = autosomal dominant
AR = autosomal recessive
XL = X-linked
IUGR = intrauterine growth restriction
1.
Geleophysic dysplasia. Major findings are likely to be present in the first year of life. Cardiac and
respiratory involvement result in death before age five years in approximately 33% of individuals
with geleophysic dysplasia 1.
2.
Weill-Marchesani syndrome. The ocular problems, typically recognized in childhood, include
microspherophakia (small spherical lens), myopia secondary to the abnormal shape of the lens,
ectopia lentis (abnormal position of the lens), and glaucoma, which can lead to blindness

Management
Evaluations Following Initial Diagnosis
To establish the extent of disease and needs in an individual diagnosed with Myhre syndrome,
the following are recommended (if not completed previously as part of the diagnostic
evaluation).
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Cardiovascular
Upper- and lower-extremity blood pressure measurements
Two-dimensional echocardiography with Doppler
For those with abnormal findings, more extensive imaging if indicated including cardiac
catheterization to document the characteristic hemodynamics of restrictive cardiomyopathy
Respiratory
Assessment for airway stenosis by the least invasive means possible with assessment for signs of
upper-airway obstruction including noisy breathing, work of breathing, and oxygen saturation
Assessment of pulmonary function and oxygen saturation for evidence of obstructive or
restrictive lung disease
Gastrointestinal. Based on clinical indication (by least invasive means possible), evaluate for
evidence of stenosis.
Neuropsychiatric. Neuropsychometric evaluation may be indicated for individuals with autistic
behaviors and/or cognitive involvement.
Other
Ophthalmology evaluation
Speech evaluation
Audiology evaluation
Consultation with a clinical geneticist and/or genetic counselor
Treatment of Manifestations
Treatment is largely symptomatic and may include the following.
Cardiovascular
Management by a cardiologist trained in congenital heart disease, including pericardial disease
and restrictive cardiomyopathy. At present, no evidence suggests that in Myhre syndrome
management of specific lesions would differ from standard care in current clinical practice,
except that any unnecessary instrumentation should be avoided as associated tissue trauma
may induce stenosis and the scarring-type tissue response unique to Myhre syndrome.
Affected individuals who are in heart failure should be under the care of a cardiovascular
specialist with access to a transplant center.
Maximize all medical treatment and minimize instrumentation for all cardiac studies and
therapies.
Medical treatment of systemic hypertension and pulmonary hypertension (based on underlying
cause).
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Respiratory
Affected individuals have required long-term tracheostomy due to complete and recurrent
tracheal stenosis following multiple and/or traumatic intubations [McGowan et al 2011,
Oldenburg et al 2015, Starr et al 2015]. To avoid traumatic intubation, consider using a sizesmaller uncuffed endotracheal tube. Elective tracheal surgery/intubation should be avoided;
tracheal resection is contraindicated [Oldenburg et al 2015].
Symptomatic treatment of restrictive lung disease
Oxygen supplementation as necessary
Gastrointestinal
Minimal instrumentation of the gastrointestinal tract is advised because post-operative
adhesions can be fatal [Lindor et al 2012].
Endoscopy should be approached with caution to avoid airway manipulation which increases
the risk for tracheal/laryngeal scarring/stenosis [Oldenburg et al 2015]. Noninvasive 3D imaging
may be preferred.
Aggressive management of constipation (through dietary means or medication if necessary) is
indicated.
Global developmental delay / intellectual disability educational issues. The following
information represents typical management recommendations for individuals with
developmental delay / intellectual disability in the United States; standard recommendations
may vary from country to country.
Ages 0-3 years. Referral to an early intervention program is recommended for access to
occupational, physical, speech, and feeding therapy. In the United States, early intervention is a
federally funded program available in all states.
Ages 3-5 years. In the United States, developmental preschool through the local public school
district is recommended. Before placement, an evaluation is made to determine needed services
and therapies and an individualized education plan (IEP) is developed.
Ages 5-21 years. In the United States, an IEP based on the individual's level of function should be
developed by the local public school district. Affected children are permitted to remain in the
public school district until age 21.
Discussion about transition plans including financial, vocation/employment, and medical
arrangements should begin at age 12 years. Developmental pediatricians can provide assistance
with transition to adulthood.
All ages. Consultation with a developmental pediatrician is recommended to ensure the
involvement of appropriate community, state, and educational agencies and to support parents
in maximizing quality of life. Some issues to consider:
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Private supportive therapies based on the affected individual’s needs may be considered.
Specific recommendations regarding type of therapy can be made by a developmental
pediatrician.
In the United States:
Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a public
agency that provides services and support to qualified individuals. Eligibility differs by state but
is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.
Families with limited income and resources may also qualify for supplemental security income
(SSI) for their child with a disability.
Social/behavioral issues
Children may qualify for and benefit from interventions used in treatment of autism spectrum
disorder, including applied behavior analysis (ABA). ABA therapy is individualized therapy
targeted to each child's behavioral, social, and adaptive strengths and weaknesses and is
typically performed one on one with a board-certified behavior analyst.
Consultation with a developmental pediatrician may be helpful in guiding parents through
appropriate behavioral management strategies or providing prescription medications when
necessary.
Individualized behavioral therapy or pharmacologic treatment for anxiety, depression, or other
psychological manifestations as per current clinical practice is appropriate.
Hearing
Hearing loss. Appropriate hearing augmentation (see Deafness and Hereditary Hearing Loss
Overview)
Persistent middle ear effusions. Myringotomy tubes as needed
Craniofacial
Individuals with orofacial clefting or velopharyngeal insufficiency should be referred to a
craniofacial clinic with pediatric experience. These individuals benefit most from a
multidisciplinary approach to care.
A craniofacial clinic associated with a major pediatric medical center usually includes a surgical
team (craniofacial surgeon and neurosurgeon), clinical geneticist, ophthalmologist,
otolaryngologist, pediatrician, radiologist, psychologist, multiple dental specialists, audiologist,
speech therapist, and social worker.
Skeletal
Consider physical therapy to keep joints mobile (no study has been done on efficacy). Note: It is
not known if passive range of motion exercises help maintain flexibility.
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A systematic study of growth hormone treatment for short stature has not been done. One
affected individual has been noted to have anecdotal improvement in growth velocity; however,
it is unknown if adult height would be affected [Starr et al 2015].
Ophthalmology. Routine treatment of strabismus and refractive errors. Note: Complications
from surgical repair have not been reported.
Prevention of Secondary Complications
Limiting tissue trauma appears to be the single most important preventive measure: The
literature suggests increased risk of proliferative fibrosis following otherwise uncomplicated
endotracheal intubation and surgical procedures. When possible, alternative noninvasive
approaches should be pursued during diagnosis and management [Oldenburg et al 2015, Starr
et al 2015].
Extreme care with intubation and use of an endotracheal tube without a cuff (or careful
monitoring of pressures with a cuff) may help prevent airway stenosis [Oldenburg et al 2015].
Minimize abdominal and pelvic procedures as extensive adhesions may develop postoperatively
[Lindor et al 2012].
Hysterectomy should be an option of last resort for treatment of menorrhagia as post-surgical
fibrosis is highly likely.
Surveillance
Cardiovascular
After normal baseline evaluations of upper- and lower-extremity blood pressure measurements,
two-dimensional echocardiography with Doppler, and cardiology evaluation
In asymptomatic individuals with a normal echocardiogram at the time of initial diagnosis,
repeat echocardiogram every 1-3 years. Note that pericardial effusion and restrictive
cardiomyopathy may occur at any age and may be clinically asymptomatic [Starr et al 2015,
Garavelli et al 2016, Lin et al 2016].
In individuals with abnormal findings at the time of initial diagnosis, more extensive imaging
may be indicated given the progressive nature of the disorder (e.g., MRI to evaluate for
pericardial thickening or effusion).
Respiratory
Consider oxygen saturation in children, with monitoring as needed for symptoms suggestive of
restrictive/obstructive pulmonary disease and annual pulmonary function studies in children
older than age six years if able to cooperate with test maneuvers.
Evaluation for upper airway stenosis (e.g., laryngotracheal stenosis) should be considered based
on symptoms.
Other
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Annual ophthalmologic and audiology evaluations
Monitoring of physical skill development and joint mobility
Agents/Circumstances to Avoid
Patients should be aggressively counseled not to smoke.
Limiting tissue trauma appears to be the single most important preventive concept in this
disorder to communicate to all health care providers involved in their care (see Prevention of
Secondary Findings).
Evaluation of Relatives at Risk
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling
purposes.
Therapies Under Investigation
Search ClinicalTrials.gov in the US and www.ClinicalTrialsRegister.eu in Europe for access to
information on clinical studies for a wide range of diseases and conditions. Note: There may not
be clinical trials for this disorder.
Genetic Counseling
Genetic counseling is the process of providing individuals and families with information on the
nature, inheritance, and implications of genetic disorders to help them make informed medical
and personal decisions. The following section deals with genetic risk assessment and the use of
family history and genetic testing to clarify genetic status for family members. This section is not
meant to address all personal, cultural, or ethical issues that individuals may face or to
substitute for consultation with a genetics professional. —ED.
Mode of Inheritance
Myhre syndrome is inherited in an autosomal dominant manner.
Risk to Family Members
Parents of a proband
All probands with Myhre syndrome reported to date have the disorder as a result of a de novo
SMAD4 pathogenic variant (see Bassett et al [2016]; Lin et al [2016] and references therein).
Recommendations for the evaluation of parents of a proband with an apparent de novo
pathogenic variant include molecular genetic testing.
Sibs of a proband. If the SMAD4 pathogenic variant found in the proband cannot be detected in
the leukocyte DNA of either parent, the risk to sibs is presumed to be slightly greater than that
of the general population (though still <1%) because of the theoretic possibility of parental
germline mosaicism.
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Offspring of a proband. To date, individuals with Myhre syndrome are not known to reproduce
and fertility has not been assessed.
Other family members. The risk to other family members is presumed to be low given that all
probands with Myhre syndrome reported to date have the disorder as a result of a de novo
SMAD4 pathogenic variant (i.e., no familial cases of Myhre syndrome have been reported).
Related Genetic Counseling Issues
Family planning
The optimal time for determination of genetic risk and discussion of the availability of prenatal
testing is before pregnancy.
It is appropriate to offer genetic counseling (including discussion of potential risks to offspring
and reproductive options) to parents of affected individuals.
DNA banking is the storage of DNA (typically extracted from white blood cells) for possible
future use. Because it is likely that testing methodology and our understanding of genes, allelic
variants, and diseases will improve in the future, consideration should be given to banking DNA
of affected individuals.
Prenatal Testing and Preimplantation Genetic Diagnosis
Once the SMAD4 pathogenic variant has been identified in an affected family member, prenatal
testing for a pregnancy at theoretic increased risk and preimplantation genetic diagnosis for
Myhre syndrome are possible.
Resources
GeneReviews staff has selected the following disease-specific and/or umbrella support
organizations and/or registries for the benefit of individuals with this disorder and their families.
GeneReviews is not responsible for the information provided by other organizations. For
information on selection criteria, click here.
National Library of Medicine Genetics Home Reference
Myhre syndrome
Alexander Graham Bell Association for the Deaf and Hard of Hearing
3417 Volta Place Northwest
Washington DC 20007
Phone: 866-337-5220 (toll-free); 202-337-5220; 202-337-5221 (TTY)
Fax: 202-337-8314
Email: info@agbell.org
Listening and Spoken Language Knowledge Center
American Society for Deaf Children (ASDC)
800 Florida Avenue Northeast
Suite 2047

51
Washington DC 20002-3695
Phone: 800-942-2732 (Toll-free Parent Hotline); 866-895-4206 (toll free voice/TTY)
Fax: 410-795-0965
Email: info@deafchildren.org; asdc@deafchildren.org
www.deafchildren.org
National Association of the Deaf (NAD)
8630 Fenton Street
Suite 820
Silver Spring MD 20910
Phone: 301-587-1788; 301-587-1789 (TTY)
Fax: 301-587-1791
Email: nad.info@nad.org
www.nad.org
Molecular Genetics
Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the
GeneReview: tables may contain more recent information. —ED.

Table A.
Myhre Syndrome: Genes and Databases

Gene

Chromosome
Locus

SMAD4 18q21.2

Protein

Mothers against
decapentaplegic homolog
4

Locus-Specific HGMD ClinVar
Databases
SMAD4
Database
SMAD4
database

SMAD4 SMAD4

Data are compiled from the following standard
references: gene from HGNC; chromosome locus from OMIM; protein from UniProt. For a
description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click here.

Table B.
OMIM Entries for Myhre Syndrome (View All in OMIM)

139210 MYHRE SYNDROME; MYHRS
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600993 MOTHERS AGAINST DECAPENTAPLEGIC, DROSOPHILA, HOMOLOG OF, 4;
SMAD4

Molecular Genetic Pathogenesis
Myhre syndrome is caused by a heterozygous SMAD4 gain-of-function pathogenic variant that
confers stability on the abnormal SMAD4 protein due to an apparent decrease in
monoubiquitination. This disrupts TGFβ signaling, thus altering expression of downstream target
genes encoding TGFβ and bone morphogenic proteins (BMP), resulting in abnormal
development of the axial and appendicular skeleton, cardiac muscle, and central nervous system
[Caputo et al 2012, Le Goff et al 2014].
In contrast, heterozygosity for a loss-of-function SMAD4 pathogenic variant has been well
established as the cause of a spectrum of acquired cardiac diseases, including cardiac fibrosis
and hypertrophy, aortopathies, atherogenesis, and pulmonary artery hypertension.
Gene structure. The coding exons 2-12 of SMAD4 constitute a 552-residue protein composed of
two domains. Exon 1 is noncoding.
Pathogenic variants. The four pathogenic variants reported to date are missense variants that
are restricted to residues 496 and 500 (Table 3). No inactivating deletions or duplications have
been reported in individuals with Myhre syndrome.
Since 2011, when heterozygosity for a SMAD4 pathogenic variant was found to be causative, 55
affected individuals with a molecularly confirmed diagnosis of Myhre syndrome have been
reported. Lin et al [2016] reported four affected individuals and summarized findings in 50
previously reported individuals [Le Goff et al 2011, Al Ageeli et al 2012, Asakura et al 2012,
Caputo et al 2012, Lindor et al 2012, Picco et al 2013, Ishibashi et al 2014, Kenis et al 2014,
Michot et al 2014, Hawkes & Kini 2015, Oldenburg et al 2015, Starr et al 2015]. Subsequently
Bassett et al [2016] reported one additional affected individual.
Table 3.

SMAD4 Pathogenic Variants Discussed in This GeneReview

DNA Nucleotide Change Predicted Protein Change Reference Sequences
c.1486C>T

p.Arg496Cys

c.1498A>G

p.Ile500Val

NM_005359.5
NP_005350.1
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DNA Nucleotide Change Predicted Protein Change Reference Sequences
c.1499T>C

p.Ile500Thr

c.1500A>G

p.Ile500Met

Note on variant classification: Variants listed in the table have been provided by the
authors. GeneReviews staff have not independently verified the classification of variants.
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human
Genome Variation Society (varnomen.hgvs.org). See Quick Reference for an explanation of
nomenclature

Note on variant classification: Variants listed in the table have been provided by the authors.
GeneReviews staff have not independently verified the classification of variants.
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human
Genome Variation Society (varnomen.hgvs.org). See Quick Reference for an explanation of
nomenclature.
Normal gene product. The three functional classes of SMADs are:
SMAD4 that encodes a SMAD protein known as the co-mediator of the SMADs;
SMAD1, SMAD2, SMAD3, SMAD5, and SMAD8 that are the receptor-regulated SMADs (or RSMADs);
SMAD6 and SMAD7 that are inhibitory SMADs.
SMAD4 (mothers against decapentaplegic homolog 4) forms heterodimers with the receptorregulated SMADs, which are translocated to the nucleus of the cell, which then (via an unclear
mechanism) regulates the expression of TGBβ and BMP pathway genes.
The 11 coding exons of SMAD4 constitute a 552-residue protein composed of two domains [Shi
& Massague 2003, Le Goff et al 2011, Caputo et al 2012]:
Mad homology 1 (MH1), which contributes to DNA binding
Mad homology 2 (MH2), which activates transcription
Abnormal gene product. Codons 496 and 500 are in the Mad homology 2 domain; pathogenic
variants in these codons confer a gain of function to the protein. The work of Le Goff et al [2011]
indicated that defective transcriptional regulation during development plays a significant role in
the disorder.
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Cancer and benign tumors. Although germline SMAD4 loss-of-function (inactivating) pathogenic
variants predispose to hamartomatous polyps in the gastrointestinal track (see Juvenile
Polyposis Syndrome), the gain-of-function pathogenic variants associated with Myhre syndrome
show no such associations (see Clinical Description, Neoplasia).
Note that somatic inactivation of SMAD4, a gastrointestinal malignancy-specific tumor
suppressor gene, is found in one third of colorectal cancer specimens and half of pancreatic
tumors. See Chen et al [2014] and references therein.
Chapter Notes
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ABSTRACT

PIGQ (OMIM *605754) encodes phosphatidylinositol-glycan biosynthesis class Q
(PIGQ) and is required for proper function of the N-acetylglucosomine (GlcNAc)
transferase complex in a similar manner to the more established PIGA, PIGC, and PIGH.
There are two previous patients reported with homozygous and apparently deleterious
PIGQ mutations. Here we provide the first detailed clinical report of a patient with
heterozygous deleterious mutations associated with a glycosylphosphatidylinositolanchored protein (GPI-AP) biosynthesis deficiency. Our patient died at 10 months of age.
The rare skeletal findings in this disorder expand the differential diagnosis of long bone
radiolucent lesions and sphenoid wing dysplasia. This clinical report describes a new and
rare disorder — PIGQ GPI-AP biosynthesis deficiency syndrome.
Keywords: inherited glycosylphosphatidylinositol-anchored protein (GPI-AP) deficiency,
PIGQ, developmental delay, bone lesion, sphenoid wing dysplasia
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INTRODUCTION

The inherited congenital disorders of glycosylation include a subset of disorders
that include genes involved in GPI-AP biosynthesis and attachment. When damaged,
these phosphatidylinositol-glycan (PIG) genes lead to a variety of clinical features
including global developmental delay, multiple congenital anomalies, hypotonia, and
epileptic seizures.

Collectively, these associated syndromes are inherited GPI-AP

biosynthesis deficiencies, with specificity derived from the precise gene involved in each
condition. PIGQ (OMIM *605754) encodes phosphatidylinositol-glycan biosynthesis class
Q (PIGQ) and is required for proper function of the GlcNAc transferase complex in a similar
manner to PIGA, PIGC, and PIGH. PIGQ was shown to be critical for the GPI biosynthesis
in in vitro studies as early as 2001 (Tiede et al., 2001). There are two prior reports of
patients with deleterious PIGQ mutations.

Both reports were complicated by

consanguinity with multiple regions of homozygosity, limited clinical information, and no
photographs or radiographs. (Alazami et al., 2015; Martin et al., 2014).

Herein, we describe a patient with a multisystem disorder and compound
heterozygous deleterious changes in PIGQ.

His clinical features included coarse,

dysmorphic facial features, pectus excavatum, marked abdominal laxity, and deep plantar
creases. He had multisystem involvement with epileptic seizure disorder, ophthalmic
anomalies, cyclical vomiting, hepatic nodule, bilateral cystic renal dysplasia, prune-bellylike abdomen, and bilateral inguinal hernias. Skeletal anomalies included sphenoid wing
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dysplasia, progressive scoliosis and metaphyseal radiolucent lesions in the femora and
tibiae.
CLINICAL REPORT
The patient was the third child of nonconsanguineous parents. He was born at 39
weeks gestation at a weight of 3.6 kg via repeat C-section. Pregnancy was complicated
by severe polyhydramnios requiring multiple amniocentesis fluid reduction procedures.
Prenatal microarray was normal. He was discharged to home at 4 days of age without
any recorded medical concerns. Parents noted he had some difficulty feeding and
trembling episodes in the newborn period. At 2 months of age there were times where
he would gasp and flail his arms. An EEG done at that time was unremarkable, but the
episodes in question were not captured during the recording. Neurologic examination,
including deep tendon reflexes specifically, was noted by his neurologist to be normal for
age.
By 4 months of age (6.3 kg, 15th centile, length: 61 cm 5th centile, head: 43 cm
85th centile), lack of head control, episodes of gasping with lip quivering, central apnea
diagnosed via sleep study, and poor feeding prompted further imaging and surveillance.
At that time, he could independently raise his head and was suspected to have vision loss
due to lack of fixation or tracking. Facial and physical characteristics included coarse facial
features, hooded upper eyelids with mild ptosis, telecanthus, fleshy and uplifted ear
lobes, thick alae nasi with broad nasal tip, and anteverted nares. He had full, almost
pendulous, cheeks, a long and smooth philtrum, thin vermilion of the upper lip, down-
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turned corners of the mouth, and mild micrognathia. He also had pectus excavatum,
diastasis recti, bilateral inguinal herniae, abdominal wall laxity, soft and sagging skin, and
deep plantar creases (Fig. 1). He began to have frequent episodes of vomiting and
decreased oral intake. His neurologist noted at 5 months of age that his truncal hypotonia
had progressed and his deep tendon reflexes were reduced to 1+.
Ophthalmic involvement included vertical nystagmus, bilateral hyperopia with
astigmatism, cortical visual impairment, delayed visual maturation, punctate keratitis of
both eyes, and alacrima with decrease of corneal sensation. Cardiovascular system
involvement was only significant for a patent foramen ovale identified at 17 weeks of age.
Assessment of the gastrointestinal/hepatic systems revealed heterogeneous liver
echotexture, right hepatic-lobe lesion (8 x 5 x 6 mm), and normal liver function studies. A
cyclic-vomiting disorder developed that required multiple hospital admissions for
intravenous fluids. The right kidney (Fig. 2) was small with increased cortical echogenicity
and diminished cortical medullary differentiation. Both kidneys had multiple small renal
cortical cysts and a triangular focus of hyperechogenicity near the lower pole papilla with
twinkle artifact representing calcification or calculi. There was grade three vesicoureteral
reflex on the right and grade one on the left. Renal function was otherwise normal until
just prior to death.
At age 7-months the patient had persistent clusters of myoclonic jerks with
extremity stiffening, lip quivering, back-arching with upper extremities appearing floppy,
and decreased responsiveness. Repeat sleep/awake EEG done at this time showed
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frequent epileptiform discharges arising from the right temporal, central and bilateral
occipital areas. Keppra was initiated with a goal of titration to 20mg/kg/day.
Unfortunately, the child was noted to have refractory irritability interfering with sleep and
oral intake. He was admitted at this time for epileptic seizure and was given lorazepam.
He was loaded with fosphenytoin (20PE/kg) resulting in resolution. The episode lasted a
total duration of approximately 33 minutes. He returned to previous baseline after
overnight admission. An EEG done the next day showed high amplitude diffuse
background slowing but no focal, lateralizing, or epileptiform patterns. Keppra was not
resumed and the child was started on phenobarbital at 3mg/kg/day instead. At 9 months
of age, a follow-up EEG showed multifocal epileptiform activity in the form of high
amplitude spike and slow wave complexes in the right occipital region, as well as spikes
and polyspikes with associated slow potentials in bilateral temporal and posterior
temporal regions. The infant developed an erratic sleeping pattern with an average of
only 4 hours of sleep per day. He also acquired cyclical vomiting with intractable
trembling, followed by crying episodes. Phenobarbital was therefore increased to
approximately 5mg/kg/day. Clonidine was also trialed for continued episodes of emesis
with minor improvement.
At 10 months of age (weight: 7.8 kg 5th centile, length: 69 cm < 2%, and head
measured 45 cm 50th centile) he presented with increased work of breathing and
tachycardia. There were sick contacts in the family. He was found to have leukocytosis
and severe respiratory acidosis and was therefore transferred to the pediatric intensive
care unit for further care. He was febrile during the hospital stay but all cultures remained
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negative with negative respiratory viral panel. Over the next 3 days his respiratory status
stabilized and he was therefore transferred to the pediatric ward. He was trialed on
gabapentin along with increase in clonidine for worsening episodes of vomiting during
this admission. The fourth day after admission he was noted to have an epileptic seizure
activity in the setting of high fever. Multiple doses of phenobarbital and fosphenytoin
eventually led to resolution, but this was followed by respiratory failure, hypotension, and
pulseless electrical activity that did not respond to resuscitative efforts resulting in
demise. Parents did not want an autopsy to be performed.
MRI of the brain at 5 months of age and CT of the brain at 10 months of age, done
for the significant change in mental status, revealed plagiocephaly with ventriculomegaly
(left>right) (Fig. 3). The skeletal findings (Fig. 4) included a large anterior fontanelle,
sphenoid wing dysplasia and an intrasutural bone of the coronal suture. Thoracolumbar
scoliosis and pectus excavatum were apparent by 6 months of age and progressed until
death. Transient radiolucent lesions of the long bones were seen on his first osseous
survey at 3 months of age.

There was resolution of the proximal tibial lesions,

enlargement of distal right femoral metaphysis lesion, and a new cortical lucency in the
right femoral neck on subsequent radiographs at 10 months of age. Alkaline phosphatase
levels were elevated throughout his life at 480-836 U/L (reference: 150 - 440 U/L).
Attempts to obtain a sample for flow cytometry were unsuccessful.
Whole exome sequencing performed at age 4-months revealed a maternal
frameshift mutation c.968_969delTG (p.L323Pfs*119) resulting in premature protein
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truncation and a paternal origin in-frame deletion c.1199_1201delACT (p.Y400del) at
position 400, which is completely conserved in vertebrates (0.02% frequency in ExAC
database), in PIGQ. The mutations of this patient were previously reported as predicted
to be highly deleterious by the laboratory that did the exome sequencing in an article
demonstrating effectiveness of identifying candidate genes of disease from exome
sequencing (Farwell Hagman et al., 2018).
DISCUSSION
Patients with the variety of PIG GPI-AP disorders share some resemblance to our
patient. Global developmental delays, epileptic seizures, and dysmorphic features affect
nearly all patients, and ophthalmic, renal, and skeletal anomalies (Bellai-Dussault,
Nguyen, Baratang, Jimenez-Cruz, & Campeau, 2018; Nguyen et al., 2018) are common.
Individuals with PIGT- and PIGA- associated GPI-AP deficiency share some of the rarer
features, including anteverted nares, uplifted fleshy ear lobes, proximally placed great
toes, and deep plantar creases (Lam et al., 2015; Tarailo-Graovac et al., 2015; Yang et al.,
2018).
The bone lesions reported here are the first such findings reported in patients with
GPI-AP deficiency disorders. PIGQ-associated (GPI-AP) deficiency expands the short
differential diagnosis for the association of ill-defined radiolucent long bone lesions and
sphenoid wing dysplasia. Our patient had normal sequencing with deletion/duplication
analysis of NF1; completed in response to the sphenoid wing dysplasia.

Infantile

myofibromatosis and congenital syphilis were also on the differential diagnosis, but
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neither fit his clinical findings.
PIGQ is involved in the initial phase of GPI-anchor biosynthesis. Because GPIanchors are required to attach proteins to the cell surface during embryogenesis,
structural development is compromised across most body systems. We postulate that
our patient with disrupted PIGQ function could not appropriately utilize bone minerals
including phosphorous, calcium, and magnesium because of the lack of proper
attachment of alkaline phosphatase to the osteoblast. This may explain the migrating
radiolucent bone lesions that our patient exhibited on osseous surveys.
To our knowledge, this is the first clinical report of a patient with compound
heterozygous mutations in PIGQ and he is the third patient with suspected PIGQ-related
disorder (Alazami et al., 2015; Martin et al., 2014). The patient described by Martin et al
(2014) had Ohtahara syndrome with homozygous PIGQ mutations discovered through
whole genome sequencing. The mutation was in a conserved splice acceptor site of exon
3 (homozygous c.690-2A>G), which induced exon-skipping resulting in an in-frame
deletion of 44 amino acids. This patient, born to consanguineous parents, had dysmorphic
craniofacial features, hypotonia, vision problems, gastrostomy-tube dependency, and
profound developmental delay. The Martin group further showed the patient's variant
was pathogenic when, in vitro, they could not restore expression of GPI-anchored
proteins to wild type levels in PIGQ-deficient Chinese hamster ovary cells, suggesting a
loss-of-function. This patient died at 2 years of age during a severe respiratory illness. One
additional patient, also born to consanguineous parents, was noted in a supplementary
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table by Alazami et al., in 2015 with homozygous c.619C>Tp.R207* mutations proposed
to be the etiology of epilepsy, optic atrophy, and developmental delay.
Taken together, the three patients support evidence for a new syndrome — PIGQrelated GPI-AP biosynthesis deficiency syndrome. Phenotypic variability is expected to
increase with ongoing reports of these patients. With improved sequencing diagnostic
tools now available and more rapid processing, PIG GPI-AP biosynthesis deficiencies will
be identified earlier. Treatments based on improving the underlying process may
improve the quality of life for these patients.
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FIGURE LEGENDS

CHAPTER 3., FIGURE 1. Newborn through 9 months of age. Coarse facial features,
hooded upper eyelids, telecanthus, mild ptosis, fleshy and uplifted ear lobes, thick ala
nasi with broad nasal tip and anteverted nares, long and smooth philtrum, thin
vermillion of the upper lip, down-turned corners of the mouth, mild micrognathia
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(A,B,C,D,E,F,G). Abdominal wall laxity (C, D), sagging skin (A,D,E,F), diastasis recti (D),
pectus excavatum (H), and deep plantar creases (I).

CHAPTER 3., FIGURE 2. Right kidney was small with increased cortical echogenicity and
diminished cortical medullary differentiation, multiple small cortical cysts.
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CHAPTER 3., FIGURE 3. MRI of the brain at 5 months (A) and CT of the brain at 10
months (B) revealed left greater than right ventriculomegaly and worsening cranial
plagiocephaly.

CHAPTER 3., FIGURE 4. Skeletal findings. Intrasutural bone (A), sphenoid wing dysplasia
at 3 months (B) and 10 months (C). Chest and abdomen radiographs at 3 (D) and 10 (E)
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months of age. Note worsening of thoracolumbar scoliosis. (F) 3 months. There are Illdefined radiolucent areas in the metaphyses of the right femur and tibia. (G) 10 months.
Compared to the films obtained at age 3 months (F) the femoral lesion has expanded,
the tibial lesion has disappeared.
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